Clinical Trials Logo

Other clinical trials

View clinical trials related to Other.

Filter by:

NCT ID: NCT03284333 Completed - Clinical trials for Acne Scars - Mixed Atrophic and Hypertrophic

enLighten Laser With MLA Handpiece for Treatment of Moderate and Severe Acne Scars

Start date: July 27, 2017
Phase: N/A
Study type: Interventional

The purpose of this pivotal investigation is to evaluate the efficacy and safety of the Cutera enlighten multi-wavelength 532 nm and 1064 nm Nd:YAG picosecond pulse duration laser and an investigational micro-lens array (MLA) handpiece attachment for improvement of acne scars.

NCT ID: NCT03284216 Completed - Hyperglycemia Clinical Trials

Hyperglycemia and Exercise.

GlucotoxEx
Start date: August 1, 2017
Phase: N/A
Study type: Interventional

This study will determine whether exposure to short-term high blood glucose levels impairs exercise-induced adaptations in glucose tolerance, and whether the pattern of high blood glucose levels plays a role.

NCT ID: NCT03284138 Completed - Clinical trials for Schizophrenia Patients With First Rank Symptoms

Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of First Rank Symptoms (FRS) on Schizophrenia

Schirang
Start date: August 3, 2018
Phase: N/A
Study type: Interventional

First rank symptoms are core symptoms of schizophrenia. the investigators want to offer an integrative approach to better understanding of the mechanisms involved in the first rank symptoms and therefore, in schizophrenia, as well as the neuronal modulation mechanisms obtained by rTMS. It will be to pass a functional magnetic resonance imaging (fMRI) at rest for healthy volunteers, and for patients before and after rTMS modulation, to view brain structures activated in the resting state network, and in order to study 1. the difference of the resting-state network between healthy volunteers and people with schizophrenia, 2. if the response to rTMS boost can be predicted by resting-state network of patients before treatment and 3. if rTMS changes activations in the brain of patients. This will ultimately provide rTMS as a treatment of first rank symptoms.

NCT ID: NCT03283761 Completed - Gastric Cancer Clinical Trials

FOLFOX-A in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma

Start date: September 21, 2017
Phase: Phase 2
Study type: Interventional

This is an open label, single-arm phase II, multi-institutional trial to evaluate the efficacy and safety of the combination of nab-paclitaxel and FOLFOX (FOLFOX-A) as first line therapy for patients diagnosed with histologically-confirmed advanced gastric/GEJ adenocarcinoma.

NCT ID: NCT03283670 Completed - Clinical trials for Depressive Disorder, Major

Inhaled Nitrous Oxide for Treatment-Resistant Depression: Optimizing Dosing Strategies

NARSAD
Start date: November 22, 2016
Phase: Phase 2
Study type: Interventional

The purpose of the study aims to determine whether different concentrations of nitrous oxide (N2O) have different antidepressant effects for adults with treatment-resistant major depression.

NCT ID: NCT03283579 Completed - Clinical trials for Attention Deficit Hyperactivity Disorder

Fatty Acids and Attention Deficit and Hyperactivity Disorder Symptoms

Start date: November 2003
Phase:
Study type: Observational

This study aimed to evaluate the longitudinal association between n-6:n-3 LCPUFAs ratio in cord blood and child ADHD symptoms at 4 and 7 years old. This study was based on the INMA project, a population-based birth cohort in Spain. Higher cord blood n-6:n-3 ratio was associated with higher subclinical ADHD symptoms during early and mid-childhood.

NCT ID: NCT03283462 Completed - Aging Clinical Trials

Bioenergetics and Muscle Function Improvement With AMAZ-02 in Elderly Skeletal Muscle (ENERGIZE Trial)

Start date: February 15, 2018
Phase: N/A
Study type: Interventional

This is a randomized, double-blind, single-center, placebo-controlled Phase 2 trial enrolling 66 healthy elderly subjects (33 placebo and 33 AMAZ-02 administration) who are ≥65 and ≤ 90 years of age with evidence of low mitochondrial function. AMAZ-02 or placebo will be orally administered for 4 months.

NCT ID: NCT03283371 Completed - Clinical trials for Epilepsy, Focal Seizures, Partial Seizures

Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy

OPUS
Start date: March 20, 2018
Phase: Phase 2
Study type: Interventional

The primary efficacy objective of the study is to determine if adjunctive therapy of natalizumab 300 mg intravenous (IV) every 4 weeks reduces the frequency of seizures in adult participants with drug-resistant focal epilepsy. The secondary efficacy objective is to assess the effects of natalizumab versus placebo in drug-resistant focal epilepsy on additional measures of seizure frequency.

NCT ID: NCT03283280 Completed - Clinical trials for Dental Restoration Failure of Marginal Integrity

Clinical Performance of Short Fiber Reinforced Resin Composite Versus Indirect Nanohybrid Resin Composite Onlay Restorations.

Start date: February 1, 2018
Phase: N/A
Study type: Interventional

clinical performance of short fiber reinforced resin composite versus indirect nanohybrid resin composite onlay restorations in complex proximal cavities of molar teeth will be evaluated over one year.

NCT ID: NCT03282955 Completed - Clinical trials for Patients Requiring Home Parenteral Nutrition

The HOME Study (HPN With OMEGA-3)

HOME
Start date: January 8, 2018
Phase: Phase 4
Study type: Interventional

The aim of the trial is to investigate safety and tolerability of an Omega-3-FA-enriched lipid emulsion in adult patients with chronic intestinal failure in need of long-term HPN. It is aimed to show non-inferiority of the lipid emulsion Lipidem (investigational test product) in comparison to the lipid emulsion Lipofundin MCT (investigational reference product) with regard to liver function.